



CURRICULUM VITAE

NAME: Jorge F. Porras, MD

POSITION TITLE: Investigator

CORPORATE ADDRESS:

eStudySite
292 Euclid Avenue #225
San Diego CA 92114

CONTACT INFORMATION:

Telephone: (619)667-4567
Fax: (619)667-4568
e-Mail: jporras@estudysite.com

RESEARCH SITE ADDRESS #1

Optimum Health Services
A Division of eStudySite
7200 Parkway Drive, Suite 116
La Mesa, CA 91942

RESEARCH SITE ADDRESS #2

PROFESSIONAL LICENSURE: Medical License #C50395, 2000, USA

BOARD CERTIFICATIONS (if applicable): Psychiatry

EDUCATION/TRAINING:

(Include baccalaureate or other initial professional education such as nursing, postdoctoral training, GCP training.)

INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of California San Diego San Diego, CA	N/A	2000-2001	Geriatric Psychiatry Fellowship Program
Good Samaritan Regional Medical Center Phoenix, AZ	N/A	1991-1994	Psychiatry Residency Training Program
University of Texas Medical Branch Galveston, TX	M.D.	1986-1990	Medicine
University of Texas El Paso, TX	B.S.	1984	Microbiology

HOSPITAL AFFILIATIONS

Current In credentialing process for Alvarado Parkway Institute
2001-present UCSD Hospital
2000-present San Diego Count Mental Health Hospital

POSITIONS AND EMPLOYMENT:

2006-present Investigator, eStudySite, San Diego, CA
2005-2006 Sub-Investigator, California Clinical Trials, San Diego, CA
2001-present Assistant Clinical Professor, UCSD, San Diego, CA
2001-2005 Psychiatrist, North Coastal Mental Health Clinic, Oceanside, CA
2000-present Emergency Psychiatrist, Emergency Psychiatric Unit, San Diego County, CA
1997-2000 Psychiatrist, CompHealth, Inc.
1997 Emergency Psychiatrist, Psychiatric Emergency Services, Phoenix, AZ
1994-1997 Adult Outpatient Psychiatrist, ComCare, Inc., Phoenix, AZ



OTHER EXPERIENCE AND PROFESSIONAL MEMBERSHIPS:

- 2005-present Certification and hands on experience with various rating scales including but not limited to: CGI-I, CGI-S, HAM-D, MADRS, HAM-A, SAS, BARS, AIMS, etc...
- 2002 Additional Certification in Geriatric Psychiatry Subspecialty
- 1999 Diplomat of the American Board of Psychiatry and Neurology

Clinical Trials Experience:

Sleep Disorders:

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Polysomnographic Study to Assess the Efficacy and Safety of a Modified Release Formulation of study drug in Primary Insomnia Patients with Sleep Maintenance Difficulties.

A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effects of Study Drug (30mg and 90mg) on Sleep Continuity, PSG Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Subjects with Primary Insomnia.

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-center Study to Assess the Efficacy and Safety of Study Drug in Primary Insomnia Patients with Sleep Maintenance Difficulties.

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Multiple Dose Plasma Concentration-Time Profiles of Study Drug (150, 200, and 250mg) and Study Drug (200mg) in Patients With Chronic Shift Work Sleep Disorder.

A 12-month, Open-Label, Flexible Dose (100-250mg/day) Extension Study of the Safety and Efficacy of Study Drug in the Treatment of Patients with Excessive Sleepiness Associated with Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder.

A Double-Blind, Randomized, Placebo-controlled, Multi-center, 30-night Polysomnographic Study of Study Drug in Elderly Patients with Primary Insomnia.

A Double-Blind, Randomized, Placebo-Controlled, Multi-center, 30-night, Polysomnographic Study of Study Drug in Adult Patients with Primary Insomnia.

A Randomized, Double-Blind, Placebo-controlled, Multi-center, 28-day, Polysomnographic Trial of Study Drug 250mg in Transient Insomnia Induced by a Sleep Phase Advance.

A Phase III, Randomized, Double-Blind, Placebo-controlled, Outpatient Study to Assess the Efficacy and Safety of a Modified Release Formulation of Study Drug in Elderly Patients with Primary Insomnia and Sleep Maintenance Difficulties.

A Randomized, Double-Blind, Placebo-controlled Study to Determine the Long-term Efficacy and Safety of Study Drug in Adults with Chronic Insomnia.

A Phase III, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Multi-center Study to Assess the Long Term Efficacy and Safety of Study Drug in Elderly Patients with Primary Insomnia and Sleep Maintenance Difficulties.



A Multi-Center, Randomized, Double-Blind, Placebo-controlled, Parallel Study of the Efficacy and Safety of Immediate Release Tablets of 1mg, 3mg, 10mg and 20mg of Study Drug and Placebo for Sleep Initiation in a Model of Transient Insomnia in Healthy Adults.

A Randomized, Double-Blind, Placebo-controlled, Crossover Study of the Efficacy and Safety of Study Drug in Adult Patients with Insomnia Characterized by Difficulty Returning to Sleep after Middle of the Night (MOTN) Awakening.

Depressive Disorders:

An 8-week, Multi-center, Double-blind, Placebo-controlled Study Evaluating the Efficacy, Safety and Tolerability of one Fixed 100mg Dose of Study Drug in Patients with Major Depressive Disorder.

An 8-week, Double-blind, Placebo-controlled, Multi-center Study with Study Drug (10mg QD) as a Positive Control, Evaluating the Efficacy, Safety and Tolerability of a Fixed Dose of Study Drug (350mg Q12h) in Outpatients with Major Depressive Disorder.

A Multi-center, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Tolerability of Study Drug Therapy Initiated with Study Drug Versus Study Drug Monotherapy in Subjects with Insomnia and Co-existing Major Depressive Disorder.

Schizophrenia/Psychotic Disorders:

A 6-week, International, Multi-center, Double-blind, Randomized, Parallel group, Phase III Study to Evaluate the Feasibility of Switching from Immediate-release Study Drug to Sustained-release Study Drug (400-800mg/day) in Outpatients with Schizophrenia.

A Randomized, Crossover Study Evaluating the Acceptability of Unflavored Study Drug and Raspberry Flavored Study Drug in Stable Subjects with a Psychotic Disorder.

A 6-week, Multi-center, Randomized, Double-blind, Fixed dose Trial of the Efficacy and Safety of Study Drug Compared with Placebo using Positive Control in Subjects with an Acute Exacerbation of Schizophrenia.

A 6-week, Multi-center, Double-blind, Double-dummy, Randomized Comparison of the Efficacy and Safety of Sustained-release Formulation of Study Drug and Placebo in the Treatment of Acutely Ill Patients with Schizophrenia.

Effect of Antipsychotic Therapy on Insulin Sensitivity: A Comparison of Study Drugs in Patients with Schizophrenia.

A Multi-center, Double-Blind, Parallel group Study to Evaluate the Efficacy and Safety of a Flexible dose of Study Drug Compared to Placebo as an Adjunctive Therapy to an Atypical Antipsychotic Agent (s) in Subjects with Schizophrenia.

A Multi-center, Double-Blind, Double-Dummy, Placebo-controlled, Randomized, Parallel Group Study of the Efficacy and Safety of Study Drug Versus Placebo in Subjects with Schizophrenia.

A Multi-center, Double-blind, Placebo-controlled, Two-Arm Flexible dose Efficacy and Safety Trial with Study Drug (250-750mg BID) in Subjects with Acutely Exacerbated Schizophrenia.



A Multi-center, Double-blind, Flexible dose, 6month Trial Comparing the Efficacy and Safety of Study Drug in Stable Subjects with Predominant, Persistent Negative Symptoms of Schizophrenia.

A Double-blind, 8-week, Placebo and Study drug-controlled, Dose-finding Trial to Evaluate the Efficacy, Safety and Tolerability of Study Drug in the Treatment of Patients with Schizophrenia or Schizoaffective Disorder.

A Randomized, Double-blind, Placebo and Ziprasidone-controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of a 24mg/day Study Drug dose Given BID for 28days to Schizophrenic Patients in Acute Exacerbation Followed by a Long-term Treatment Phase.

A Randomized, Double-blind, Multi-center Study to Assess the Antipsychotic and Motor Effects of Study Drug When Administered in Combination with Study Drug in Schizophrenic Subjects.

A Multi-center, Double-blind, Randomized, Parallel Group, Active-controlled Tolerability and Safety Trial in Outpatients with Clinically Stable Schizophrenia.

Anxiety Disorders:

A 28-day, Multi-center, Randomized, Placebo-controlled, Double-blind Trial of Study Drug in Healthy Subjects and Patients with Generalized Anxiety Disorder.

A 10-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Flexible Dosage Study to Evaluate the Efficacy and Safety of Study Drug in the Treatment of Adults with Generalized Anxiety Disorder.

A 12-month, Open-Label, Flexible Dosage Study to Evaluate the Safety and Efficacy of Study Drug Treatment in Adults with Generalized Anxiety Disorder.

An 8-week, Double-Blind, Placebo-controlled, Multi-center Study with Study Drug as a Positive Control, Evaluating the Efficacy, Safety and Tolerability of a Fixed Dose of Study Drug in Outpatients with Generalized Anxiety Disorder.

Miscellaneous:

A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-Ranging Study to Evaluate the Phase-Shifting Effects of Repeated Daily Dosing of Study Drug in Health Subjects.

A Phase II, Double-blind, Placebo-controlled, Randomized, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of 40mg/day Study Drug in Subjects with Restless Leg Syndrome.